FDA approves Rituxan for two rare disorders

The US Food and Drug Administration has approved Rituxan (rituximab), in combination with glucocorticoids, to treat patients with Wegener’s granulomatosis and microscopic polyangiitis, two rare disorders that cause blood vessel inflammation.